List of works - Ronit Simantov

A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

scientific article published on 11 September 2014

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

scientific article

Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

scientific article

Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis

scientific article published on 01 November 1997

Antiphospholipid antibodies activate vascular endothelial cells

scientific article published on 01 October 1996

CD36: a critical anti-angiogenic receptor

scientific article (publication date: September 2003)

Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.

scientific article

Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma

scientific article

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

scientific article published on October 2006

Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies

scientific article published on 01 December 1996

GPNMB expression in uveal melanoma: a potential for targeted therapy.

scientific article published on June 2010

Genetic background determines the extent of atherosclerosis in ApoE-deficient mice

scientific article published on 01 August 1999

Genomic absence of the gene encoding T cell receptor Vbeta7.2 is linked to the presence of autoantibodies in Sjögren's syndrome

scientific article published on 01 January 2004

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer

scientific article

Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.

scientific article

Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1

scientific article

Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2.

scientific article published on 28 August 2006

Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors

scientific article published on 10 September 2014

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer

scientific article published on 01 May 2007

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

scientific article published on 29 September 2014

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

scientific article published on 24 April 2006

Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.

scientific article

Sorafenib in advanced clear-cell renal-cell carcinoma

scientific article

The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein

scientific journal article

Thrombosis and malignancy: pathogenesis and prevention

scientific article published on 01 November 1998

List of works by Ronit Simantov

A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis

Antiphospholipid antibodies activate vascular endothelial cells

CD36: a critical anti-angiogenic receptor

Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.

Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies

GPNMB expression in uveal melanoma: a potential for targeted therapy.

Genetic background determines the extent of atherosclerosis in ApoE-deficient mice

Genomic absence of the gene encoding T cell receptor Vbeta7.2 is linked to the presence of autoantibodies in Sjögren's syndrome

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer

Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.

Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1

Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2.

Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.

Sorafenib in advanced clear-cell renal-cell carcinoma

The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein

Thrombosis and malignancy: pathogenesis and prevention